IRLA — IRulya Therapeutics Share Price
Last trade - 00:00- $355.93m
- $383.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -110.1% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IRulya Therapeutics, Inc., formerly Quince Therapeutics, Inc., is a clinical-stage biopharmaceutical company. It is developing a novel disease-modifying therapeutic to address the unmet medical need associated with pulmonary disorders. Its lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of pulmonary conditions associated with dysfunctional mammalian target of rapamycin activity. It is evaluating the use of LAM-001 as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and for patients with bronchiolitis obliterans syndrome post lung transplant (BOS). It also completed a Phase 2a trial, which enrolled patients with pulmonary arterial hypertension as well as patients with PH-ILD and sarcoidosis associated pulmonary hypertension (SAPH) where it achieved clinically relevant improvement across multiple endpoints, and others.
Directors
- David Lamond CHM (46)
- Christopher Lowe CEO (53)
- Leslie Holsinger EVP (55)
- Caryn McDowell CAD (51)
- Michael Detke OTH (55)
- Una Ryan LED (79)
- Margaret Mcloughlin IND (58)
- Christopher Senner IND (53)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 20th, 2012
- Public Since
- May 9th, 2019
- No. of Shareholders
- 28
- No. of Employees
- 38
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,841,470
- Address
- 601 Gateway Boulevard, Suite 1250, SOUTH SAN FRANCISCO, 94080
- Web
- https://quincetx.com
- Phone
- +1 4159105717
- Auditors
- BDO USA, LLP
Latest News for IRLA
Upcoming Events for IRLA
Q3 2026 IRulya Therapeutics Inc Earnings Release
Q4 2026 IRulya Therapeutics Inc Earnings Release
Similar to IRLA
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 03:25 UTC, shares in IRulya Therapeutics are trading at $32.83. This share price information is delayed by 15 minutes.
Shares in IRulya Therapeutics last closed at $32.83 and the price had moved by -90.98% over the past 365 days. In terms of relative price strength the IRulya Therapeutics share price has underperformed the S&P500 Index by -92.07% over the past year.
The overall consensus recommendation for IRulya Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIRulya Therapeutics does not currently pay a dividend.
IRulya Therapeutics does not currently pay a dividend.
IRulya Therapeutics does not currently pay a dividend.
To buy shares in IRulya Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $32.83, shares in IRulya Therapeutics had a market capitalisation of $355.93m.
Here are the trading details for IRulya Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IRLA
Based on an overall assessment of its quality, value and momentum IRulya Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in IRulya Therapeutics is $75.00. That is 128.45% above the last closing price of $32.83.
Analysts covering IRulya Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$7.64 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IRulya Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +12.99%.
As of the last closing price of $32.83, shares in IRulya Therapeutics were trading -53.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IRulya Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $32.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
IRulya Therapeutics' management team is headed by:
- David Lamond - CHM
- Christopher Lowe - CEO
- Leslie Holsinger - EVP
- Caryn McDowell - CAD
- Michael Detke - OTH
- Una Ryan - LED
- Margaret Mcloughlin - IND
- Christopher Senner - IND